bevacizumab

08/19/2013 - 09:00

A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.

 

05/21/2012 - 08:50

VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine and patient-tailored use of this important cancer drug.

01/02/2012 - 09:20

Treating ovarian cancer with the drug bevacizumab (“Avastin”) delays the disease and may also improve survival, according to an international clinical trial co-led by Drs. Amit Oza of PMH at UHN, and Timothy Perren, St James’s Institute of Oncology, Leeds, UK.